Home > For Consumers > Oral lactoferrin for prevention of...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2003-.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet].

Oral lactoferrin for prevention of sepsis and necrotizing enterocolitis in preterm infants

This version published: 2015; Review content assessed as up-to-date: September 06, 2014.

Link to full article: [Cochrane Library]

Plain language summary

Premature babies are at risk for blood infection (sepsis) and/or gastrointestinal injury (necrotizing enterocolitis, or NEC). A number of babies with sepsis or NEC die or develop long‐term brain and lung injury despite treatment with antibiotics. Lactoferrin, which is present in human milk, has been shown to be effective against infection when tested in animals and in the laboratory. Lactoferrin also enhances the ability of babies to fight infection. We found four studies that enrolled 1103 preterm babies. Evidence of moderate to low quality suggests that oral lactoferrin with or without a probiotic decreases sepsis and NEC in preterm infants with no adverse effects. When given alone, lactoferrin decreases deaths among preterm infants. We also found large studies that are ongoing, and their results when available may increase the strength of our analysis. Clarification regarding dosing, duration, type of lactoferrin (human or bovine), and development of preterm babies is still needed.

Abstract

Background: Lactoferrin, a normal component of human colostrum and milk, can enhance host defense and may be effective in the prevention of sepsis and necrotizing enterocolitis (NEC) in preterm neonates.

To assess the safety and effectiveness of oral lactoferrin in the prevention of sepsis and NEC in preterm neonates.

1. To determine the effects of oral lactoferrin used to prevent neonatal sepsis and/or NEC on duration of positive‐pressure ventilation, development of chronic lung disease (CLD) or periventricular leukomalacia (PVL), length of hospital stay to discharge among survivors, and adverse neurological outcomes at two years of age or later.

2. To determine the adverse effects of oral lactoferrin in the prophylaxis of neonatal sepsis and/or NEC.

When data were available, we analyzed the following subgroups.

1. Gestational age < 32 weeks and 32 to 36 weeks.

2. Birth weight < 1000 g (extremely low birth weight (ELBW) infants) and birth weight < 1500 g (very low birth weight (VLBW) infants).

3. Type of feeding: breast milk versus formula milk.

Search methods: We used the search strategy of the Cochrane Neonatal Review Group (CNRG) and updated our search in July 2014. We searched the databases Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, PREMEDLINE, EMBASE, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL), as well as trials registries and conference proceedings.

Selection criteria: Randomized controlled trials (RCTs) evaluating oral lactoferrin at any dose or duration to prevent sepsis or NEC in preterm neonates.

Data collection and analysis: Review authors used standard methods of the CNRG.

Main results: Four RCTs are included in this review. Oral lactoferrin supplementation decreased late‐onset sepsis (typical risk ratio (RR) 0.49, 95% confidence interval (CI) 0.32 to 0.73; typical risk difference (RD) ‐0.09, 95% CI ‐0.14 to ‐0.04; number needed to treat for an additional beneficial outcome (NNTB) 11, 95% CI 7 to 25; four trials, 678 participants, moderate‐quality evidence), NEC stage II or greater (typical RR 0.30, 95% CI 0.12 to 0.76; typical RD ‐0.05, 95% CI ‐0.08 to ‐0.01; NNTB 20, 95% CI 12.5 to 100; two studies, 505 participants, low‐quality evidence), and "all‐cause mortality" (typical RR 0.30, 95% CI 0.12 to 0.75; typical RD ‐0.05, 95% CI ‐0.08 to ‐0.01; NNTB 20, 95% CI 12.5 to 100; two studies, 505 participants, low‐quality evidence).

Oral lactoferrin supplementation with a probiotic decreased late‐onset sepsis (RR 0.27, 95% CI 0.12 to 0.60; RD ‐0.13, 95% CI ‐0.19 to ‐0.06; NNTB 8, 95% CI 5 to 17; one study, 321 participants, low‐quality evidence) and NEC stage II or greater (RR 0.04, 95% CI 0.00 to 0.62; RD ‐0.05, 95% CI ‐0.08 to ‐0.03; NNTB 20, 95% CI 12.5 to 33.3; one study, 496 participants, low‐quality evidence), but not "all‐cause mortality."

Oral lactoferrin with or without probiotics decreased fungal sepsis but not chronic lung disease or length of hospital stay (from one study, low‐quality evidence). No adverse effects were reported. Long‐term neurological outcomes or periventricular leukomalacia was not evaluated.

Authors' conclusions: Evidence of moderate to low quality suggests that oral lactoferrin prophylaxis with or without probiotics decreases late‐onset sepsis and NEC stage II or greater in preterm infants without adverse effects. Completion of ongoing trials will provide evidence from more than 6000 preterm neonates and may enhance the quality of the evidence. Clarifications regarding optimum dosing regimens, type of lactoferrin (human or bovine), and long‐term outcomes are still needed.

Editorial Group: Cochrane Neonatal Group.

Publication status: New search for studies and content updated (no change to conclusions).

Citation: Pammi M, Abrams SA. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database of Systematic Reviews 2015, Issue 2. Art. No.: CD007137. DOI: 10.1002/14651858.CD007137.pub4. Link to Cochrane Library. [PubMed: 25699678]

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PMID: 25699678

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...